{"id":"W4387810503","doi":"10.1016/j.annonc.2023.09.2567","title":"1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier; Eisai; Relay Therapeutics; Springworks Therapeutics; Revolution Medicines; Incyte; Novocure; Mersana Therapeutics; Eli Lilly and Company; AstraZeneca; Celgene; Ipsen; BeiGene; Sanofi; Pfizer","keywords":"Medicine; Pancreatic ductal adenocarcinoma; Adenocarcinoma; Cancer research; Antibody; Oncology; Pancreatic cancer; Internal medicine; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000270717,0.0002900419,0.0008648971,0.0001580028,0.0001923817,0.0003968403,0.0002262936,0.0004355614,0.002200801],"category_scores_gemma":[0.000225726,0.0001267918,0.0003535475,0.0002109138,0.0002630592,0.0003372337,0.0001339584,0.001140434,0.00058451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003383179,"about_ca_system_score_gemma":0.0003453744,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005637642,"about_ca_topic_score_gemma":0.00117534,"domain_scores_codex":[0.9999213,0.00001362487,0.000006297916,0.00001331171,0.00001296093,0.00003242778],"domain_scores_gemma":[0.9998922,0.00002320775,0.00001339726,0.00001620403,0.000008858184,0.00004622759],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1069661,0.01070513,0.009692154,0.0008847368,0.0008187067,0.003704984,0.0002886189,0.005737648,0.3059088,0.001227067,0.009253937,0.5448121],"study_design_scores_gemma":[0.08159464,0.4606361,0.1080854,0.00017051,0.001958896,0.01531448,0.0003024981,0.01453475,0.2425802,0.001692353,0.07300536,0.0001248826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934382,0.002544704,0.0003202554,0.0003161412,0.0001279979,0.00005082081,0.000258363,0.0000882888,0.002855188],"genre_scores_gemma":[0.9954987,0.0009678604,0.0002360917,0.0001759466,0.00004083048,0.00002868956,0.0006432582,0.00001583654,0.002392703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002200801,"threshold_uncertainty_score":0.007362425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07373313948172684,"score_gpt":0.4170988546425355,"score_spread":0.3433657151608087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}